Martin E. Dowty

4.8k total citations · 2 hit papers
57 papers, 3.0k citations indexed

About

Martin E. Dowty is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, Martin E. Dowty has authored 57 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 21 papers in Molecular Biology and 18 papers in Pharmacology. Recurrent topics in Martin E. Dowty's work include Pharmacogenetics and Drug Metabolism (15 papers), Drug Transport and Resistance Mechanisms (10 papers) and Cytokine Signaling Pathways and Interactions (10 papers). Martin E. Dowty is often cited by papers focused on Pharmacogenetics and Drug Metabolism (15 papers), Drug Transport and Resistance Mechanisms (10 papers) and Cytokine Signaling Pathways and Interactions (10 papers). Martin E. Dowty collaborates with scholars based in United States, China and United Kingdom. Martin E. Dowty's co-authors include Sriram Krishnaswami, Michael I. Jesson, Nandini Kishore, Debra M. Meyer, Jon A. Wolff, Phillip Williams, Sujatha Menon, Jean‐Baptiste Telliez, James E. Hagstrom and Sarbani Ghosh and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Immunology and Scientific Reports.

In The Last Decade

Martin E. Dowty

56 papers receiving 2.9k citations

Hit Papers

Modulation of Innate and Adaptive Immune Responses by Tof... 2011 2026 2016 2021 2011 2016 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
    2011 514 citations Michael I. Jesson, Sarbani Ghosh et al. profile →
  2. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.
    2016 305 citations Sriram Krishnaswami, James D. Clark et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Martin E. Dowty United States 24 799 790 783 750 479 57 3.0k
Thomas T. Kawabata United States 27 355 0.4× 417 0.5× 518 0.7× 988 1.3× 255 0.5× 68 2.6k
Akari Suzuki Japan 37 506 0.6× 1.1k 1.4× 1.2k 1.5× 1.2k 1.6× 415 0.9× 100 3.6k
Cheryl Nickerson‐Nutter United States 28 572 0.7× 774 1.0× 451 0.6× 1.8k 2.4× 142 0.3× 44 3.2k
Ernest Brahn United States 28 542 0.7× 702 0.9× 1.1k 1.3× 839 1.1× 136 0.3× 64 2.5k
Jacques Jolivet Canada 29 1.0k 1.3× 1.7k 2.1× 789 1.0× 179 0.2× 217 0.5× 91 3.9k
Kah Keng Wong Malaysia 27 1.3k 1.6× 1.6k 2.0× 232 0.3× 506 0.7× 396 0.8× 111 3.7k
Susan L. Kelley United States 17 888 1.1× 1.3k 1.7× 180 0.2× 642 0.9× 217 0.5× 26 3.4k
Steven G. Nadler United States 38 587 0.7× 1.5k 1.9× 329 0.4× 1.6k 2.2× 319 0.7× 87 3.8k
Piotr Smolewski Poland 32 815 1.0× 1.8k 2.3× 166 0.2× 801 1.1× 103 0.2× 172 3.5k
A. B. Deisseroth United States 29 1.0k 1.3× 1.2k 1.5× 139 0.2× 658 0.9× 322 0.7× 79 3.1k

Countries citing papers authored by Martin E. Dowty

Since Specialization
Citations

This map shows the geographic impact of Martin E. Dowty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin E. Dowty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin E. Dowty more than expected).

Fields of papers citing papers by Martin E. Dowty

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin E. Dowty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin E. Dowty. The network helps show where Martin E. Dowty may publish in the future.

Co-authorship network of co-authors of Martin E. Dowty

This figure shows the co-authorship network connecting the top 25 collaborators of Martin E. Dowty. A scholar is included among the top collaborators of Martin E. Dowty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin E. Dowty. Martin E. Dowty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bauman, Jonathan, Angela C. Doran, Brian Hee, et al.. (2024). The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Ritlecitinib, a Janus Kinase 3 and Tyrosine-Protein Kinase Family Inhibitor, in Humans. Drug Metabolism and Disposition. 52(10). 1124–1136. 7 indexed citations
2.
Dowty, Martin E., Ruolun Qiu, Alyssa Dantonio, et al.. (2024). The Metabolism and Disposition of Brepocitinib in Humans and Characterization of the Formation Mechanism of an Aminopyridine Metabolite. Drug Metabolism and Disposition. 52(7). 690–702. 4 indexed citations
3.
Wang, X., Martin E. Dowty, Vu Le, et al.. (2024). Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy Individuals. European Journal of Drug Metabolism and Pharmacokinetics. 49(3). 367–381. 3 indexed citations
4.
5.
Plotka, Anna, Julia Kaplan, Vivek S. Purohit, et al.. (2023). Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter Activity. Pharmaceutical Research. 40(11). 2639–2651. 3 indexed citations
6.
Wang, Xiaoxing, Martin E. Dowty, Svitlana Tatulych, et al.. (2022). Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals. European Journal of Drug Metabolism and Pharmacokinetics. 47(3). 419–429. 22 indexed citations
7.
Guttman‐Yassky, Emma, Ana B. Pavel, Aisleen Diaz, et al.. (2021). Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. Journal of Allergy and Clinical Immunology. 149(4). 1318–1328. 74 indexed citations
8.
Gerstenberger, Brian S., Mary Ellen Banker, James D. Clark, et al.. (2020). Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency Differences. Scientific Reports. 10(1). 8974–8974. 7 indexed citations
9.
Guttman‐Yassky, Emma, Ana B. Pavel, Karen Page, et al.. (2019). 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1). Journal of Investigative Dermatology. 139(5). S94–S94. 5 indexed citations
10.
Banfield, Christopher, Matthew Scaramozza, Weidong Zhang, et al.. (2017). The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF‐06700841) in Healthy Subjects and Patients With Plaque Psoriasis. The Journal of Clinical Pharmacology. 58(4). 434–447. 71 indexed citations
11.
Leung, Louis, Xin Yang, Timothy J. Strelevitz, et al.. (2016). Clearance Prediction of Targeted Covalent Inhibitors by In Vitro-In Vivo Extrapolation of Hepatic and Extrahepatic Clearance Mechanisms. Drug Metabolism and Disposition. 45(1). 1–7. 25 indexed citations
12.
Dowty, Martin E., Michael I. Jesson, Sarbani Ghosh, et al.. (2013). Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis. Journal of Pharmacology and Experimental Therapeutics. 348(1). 165–173. 88 indexed citations
13.
Gupta, Pankaj, Christine Alvey, Rong Wang, et al.. (2012). Lack of effect of tofacitinib (CP‐690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation ofin vitrodata. British Journal of Clinical Pharmacology. 74(1). 109–115. 32 indexed citations
14.
Kraynov, Eugenia, Steven W. Martin, Susan Hurst, et al.. (2011). How Current Understanding of Clearance Mechanisms and Pharmacodynamics of Therapeutic Proteins Can Be Applied for Evaluation of Their Drug-Drug Interaction Potential. Drug Metabolism and Disposition. 39(10). 1779–1783. 14 indexed citations
15.
Meyer, Debra M., Michael I. Jesson, Xiong Li, et al.. (2010). Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. Journal of Inflammation. 7(1). 41–41. 384 indexed citations
16.
Cowan‐Ellsberry, Christina, Scott D. Dyer, Susan Erhardt, et al.. (2007). Approach for extrapolating in vitro metabolism data to refine bioconcentration factor estimates. Chemosphere. 70(10). 1804–1817. 95 indexed citations
17.
Meyers, Kenneth M., José Méndez-Andino, Anny‐Odile Colson, et al.. (2006). Novel pyrazolopiperazinone- and pyrrolopiperazinone-based MCH-R1 antagonists. Bioorganic & Medicinal Chemistry Letters. 17(3). 657–661. 7 indexed citations
18.
De, Biswanath, Michael G. Natchus, Stanisław Pikul, et al.. (1999). The Next Generation of MMP Inhibitors: Design and Synthesis. Annals of the New York Academy of Sciences. 878(1). 40–60. 28 indexed citations
19.
Dowty, Martin E., et al.. (1992). Transport of Thyrotropin Releasing Hormone in Rabbit Buccal Mucosa in Vitro. Pharmaceutical Research. 9(9). 1113–1122. 78 indexed citations
20.
Tucker, Ian G., Martin E. Dowty, M. Veillard, Mark A. Longer, & Joseph R. Robinson. (1989). Reversed-Phase High-Performance Liquid Chromatographic Analysis of Oligoglycines (One to Six Amino Acid Residues). Pharmaceutical Research. 6(1). 100–102. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas T. Kawabata Breakdown of academic impact, for papers by Akari Suzuki Breakdown of academic impact, for papers by Cheryl Nickerson‐Nutter Breakdown of academic impact, for papers by Ernest Brahn Breakdown of academic impact, for papers by Jacques Jolivet Breakdown of academic impact, for papers by Kah Keng Wong Breakdown of academic impact, for papers by Susan L. Kelley Breakdown of academic impact, for papers by Steven G. Nadler Breakdown of academic impact, for papers by Piotr Smolewski Breakdown of academic impact, for papers by A. B. Deisseroth
Rankless by CCL
2026